Business UpdateJul 27, 2026, 08:31 AM
PRF Technologies raises $10M, advances OcuRing-K Phase 2 trial
AI Summary
PRF Technologies issued a Letter to Shareholders detailing its first-half 2026 progress and strategic priorities. The company significantly strengthened its financial position by raising $10 million through an equity line facility. Key advancements include LayerBio progressing towards a Phase 2 clinical trial for OcuRing™-K and positive preclinical results for PRF-110. Additionally, the DeepSolar platform validated its Predict™ platform, expanded its capabilities, and joined the NVIDIA Connect program.
Key Highlights
- Raised $10 million through equity line facility.
- LayerBio advancing Phase 2 clinical trial for OcuRing™-K.
- PRF-110 showed sustained 72-hour analgesic activity in preclinical study.
- DeepSolar validated Predict™ platform with European market data.
- DeepSolar expanded platform with Battery-to-Revenue Intelligence.
- DeepSolar joined NVIDIA Connect program.
- DeepSolar to showcase GridFeed™ at Energy Trading Week Europe 2026.
Price Impact
More from PRFX